Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival.

摘要

We read with interest the article by Low etal., which found that addition of etoposide to high-dose cytarabine and idarubicin for acute myeloid leukaemia (AMI) induction chemotherapy increased gastrointestinal toxic-ity without improvement in complete remission (CR) rate or survival. This observation occurs in the setting of ongoing debate regarding optimal cytarabine and anthracycline doses, and the role of additional agents in AML induction strategies.